Royalty Report: Drugs, Stem cells, cell therapy – Collection: 383612


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 5


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 5

Primary Industries

  • Drugs
  • Stem cells
  • cell therapy
  • Medical
  • Drug Discovery
  • Supply
  • Biotechnology
  • Defense/Military
  • Disease
  • Therapeutic
  • Pharmaceuticals
  • bone marrow
  • Cancer

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 383612

License Grant
Licensor grants an exclusive, even as to Licensor, except as required for Licensor to meet its development and supply obligations hereunder, right and license, with the right to sublicense, during the Term of this Agreement under the Licensor Intellectual Property and Licensors interest in any Joint Patent Rights and Joint Technology solely to research, develop, make, have made, use, sell, offer for sale and import Products in the Field in the Licensee Territory, and a non-exclusive right and license, with the right to sublicense, during the Term of this Agreement under the Licensor Intellectual Property to research, make, have made, use and export Products in the Field in North America.
License Property
Licensor is a stem cell therapeutic leader focused on developing and marketing products to treat medical conditions and possesses broad scientific and clinical leadership in the field of human mesenchymal stem cells (MSCs) and know-how, expertise and intellectual property rights pertaining to MSCs, including its Prochymal product and Chondrogen product.

Chondrogen shall mean any formulation, dosage form or delivery system that contains culturally expanded, undifferentiated, unmodified human MSCs for local delivery for the Articulating Orthopedic Indication and any Improvements thereto.

Prochymal shall mean any formulation, dosage form or delivery system suitable for Vascular Administration that contains culturally expanded, undifferentiated, unmodified human MSCs, and any Improvements thereto.

Ulcerative Colitis Indication shall mean the use of Prochymal for the treatment or prevention of ulcerative colitis.

Mesenchymal Stem Cells or MSCs shall mean the human formative pluripotential blast cells found inter alia in bone marrow, blood, dermis and periosteum that are capable of differentiating into any of the specific types of mesenchymal or connective tissues.

COPD Indication shall mean the use of Prochymal to treat chronic obstructive pulmonary disease.

Articulating Orthopedic Indication shall mean the use of Chondrogen for preventing or treating diseases, defects or conditions of articulating joints, including cartilage and meniscus repair, osteoarthritis, osteochondral defect repair, and the treatment of acute and chronic orthopedic pain within an articulating joint.

Crohns Indication shall mean the use of Prochymal to treat Crohns disease.

Diabetes Indication shall mean the use of Prochymal for the prevention or treatment of Type I diabetes.

GvHD Indication shall mean the use of Prochymal to treat or prevent graft versus host disease.

Cardiac Indication shall mean the use of Prochymal to treat or prevent acute myocardial infarction.

Pain Therapeutic shall mean use of Chondrogen for the mitigation or relief of orthopedic pain with a Statistically Significant duration of relief of at least one year.

Field of Use
Field shall mean with respect to Prochymal, all applications for the prevention or treatment of diseases, defects, or conditions in humans, and with respect to Chondrogen, the Articulating Orthopedic Indication.

IPSCIO Record ID: 47833

License Grant
Two Spanish Licensors, including a University, have an exclusive license agreement with a Spanish Licensee of all rights to the Patent.
License Property
The agreement is for a patent under number PCT/IB2009/006597 entitled Uses of Mesenchymal Stem Cells. Licensee has the intention of applying for future international extensions of such application, hereinafter, all of them jointly referred to as the Patent.
Field of Use
Systemic inflammatory response syndrome (SIRS) is an inflammatory state of the whole body without a specific source of infection. It can be caused by many factors, including but not limited to trauma, surgery, adrenal insufficiency, pulmonary embolism, myocardial infarction, hemorrhage, anaphylaxis, drug overdose, immunodeficiency and burns. There are four major diagnostic symptoms of SIRS, as listed below, but the presence of any two of these is sufficient for a diagnosis.

IPSCIO Record ID: 346226

License Grant
University granted us an exclusive, worldwide license under such patents and a nonexclusive royalty-bearing, worldwide license for such know-how to research, develop, commercialize and manufacture FCR001 and products containing FCR001 in all fields, without limitation. University also granted us the right to grant sublicenses in accordance with the University License Agreement.
License Property
The rights granted relate to certain licensed patent rights and know-how related to human facilitating cells for the Facilitated Allo-HSCT Therapy.

Aallogeneic hematopoietic stem cell transplantation (allo-HSCT), called Facilitated Allo-HSCT Therapy.  

The product candidate, FCR001, which is central to Facilitated Allo-HSCT Therapy, is a novel allogeneic cell therapy comprised of stem and immune cells that are procured from a healthy donor, who is also the organ donor in the case of organ transplantation. FCR001 is rapidly processed in the GMP facility using proprietary manufacturing methods. Then, at the time of the transplant, FCR001 is administered to the recipient following nonmyeloablative conditioning, which is designed to be less toxic than myeloablative conditioning. A fully myeloablative conditioning regimen consists of a combination of agents and high doses of total body irradiation that destroy hematopoietic stem cells (HSCs) in the bone marrow and results in profound depletion of HSC-derived cells within one to three weeks following administration that is irreversible, and in most instances is fatal unless rescued by a stem cell transplant. The nonmyeloablative conditioning for FCR001 entails lower doses of chemotherapy and total body irradiation, causes less depletion of blood cells and does not require stem cell support for the recipient to resume the production of blood cells and platelets.

Allo-HSCT Therapy has the potential to treat a range of severe autoimmune diseases and severe non-malignant blood, immune and metabolic disorders, in each case with potential for similar outcomes to what has previously been observed with HSCT, while mitigating the toxicities, morbidities and extended hospital stay associated with the conditioning regimen typically required by HSCT.

Field of Use
Field of use is for to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases and certain severe non-malignant blood, immune and metabolic disorders, in all fields, without limitation.

Facilitated Allo-HSCT Therapy could prevent organ rejection without the morbidity and mortality that has been associated with the use of lifelong anti-rejection medicines, also known as chronic immunosuppression.

IPSCIO Record ID: 6596

License Grant
We entered into an Agreement with the Licensor for collaboration in the preparation and execution of development and purchase Agreements with United States and Allied government agencies for countermeasures to nuclear terrorism and other radiological emergencies.
License Property
Prochymal is a stem cell drug therapy.  Prochymal, which is made from mesenchymal stem cells found in adult bone marrow, is in late-stage human clinical trials for other uses, including the treatment of Crohn's disease.  Its development partner will receive development costs and a royalty on sales if the drug is approved for use.
Field of Use
In January 2008, we were awarded a contract from the United States Department of Defense for the development and stockpiling of Prochymal for the treatment of Acute Radiation Syndrome. Under the terms of the contract, the DoD will provide technology and product development funding to us up to $24.7 million. The contract further provides for additional funding for activities leading to FDA approval of Prochymal for ARS and the scaling up of manufacturing processes, and provides the DoD with successive options for the purchase of up to 20,000 doses of Prochymal in the aggregate.  We will carry out this contract in partnership with the Licensor, with us contributing Prochymal and our corresponding safety and advocacy database to the effort, and with the Licensor lending its mass product development and large scale commercialization expertise.

IPSCIO Record ID: 383557

License Grant
Licensor grants the Licensee of Japan an exclusive license in the Territory, with the right to grant sublicenses, under the Licensor Patents and Licensor Technology to develop, register and to obtain Product Registrations, use, make, have made, import, export, offer to sell, sell and have sold Products for use in the Field in the Territory.
License Property
Licensor is the owner of certain technology, including, but not limited to patents and know-how, relating to mesenchymal stem cells.

MSC shall mean human cells that are capable of differentiation into more than one mesenchymal lineage.

Product means any product or composition that contains MSC and/or any process or service performed with respect to recovery, expansion, maintenance, purification, storage, production, formulation or use of MSC.

The patents include
—  Monoclonal antibodies specific for marrow-derived mesenchymal cells;
—  Uses for non-autologus mesenchymal stem cells;
—  Osteoporosis bond regeneration;
—  Mesenchymal stem cells for prevention and treatment of immune responses in transplantation;
—  Mesenchymal stem cells as immunosuppressants;
—  Regulation of Hema topoietic stem cell  differentiation by the use of human mesenchymal stem cells;
—  Uses of fibroblasts or supernatants from fibroblasts for the suppression of immune responses in transplantation.

Field of Use
The Field means the use of MSC in or in conjunction with the treatment of hematological malignancies by the use of hematopoietic stem cells derived from peripheral blood, cord blood or bone marrow.

Hematologic malignancies are cancers that begin in blood-forming tissue, such as the bone marrow, or in the cells of the immune system. There are three main types of hematologic malignancies leukemia, lymphoma and multiple myeloma.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.